Alcon Inc ALC

$71.13 +1.30 (1.86%)

Valuation

Market cap
34,539,036,000
Revenue TTM
$10,401,000,000
Net income TTM
$980,000,000
PE ratio
21.29
Forward PE
19.85
Profit margin
9.42%
Debt to equity
0.22

Trading

Volume
1,255,500
Avg volume
1,581,252
Day's range
$70.39 – $71.35
Shares out
494,616,000
Stochastic %K
96%
Beta
0.88
Analysts
Strong Sell
Price target
$81.99

Price

Company profile

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical proced...

Show more

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Industry
Medical Instruments & Supplies
Sector
Healthcare
Phone
41 589 112 110
Website
https://www.alcon.com
Address
Chemin de Blandonnet 8, Vernier, Geneva, Switzerland

Latest news

Stocktwits

TrumpAndWorld Oct 23, 12:14 AM
Alcon is paying $550M for a neurotech pharma asset to expand its cell therapy pipeline, a bolt-on that is small relative to its ~$35BN market cap and does not change near-term revenue for $ALC or its device peers. The stock already popped 4.7% after hours on the headline, so the remaining trade is thin; Slightly Bearish
0 replies
AXLFI_HQ Oct 22, 11:17 PM
$ALC Medical-device stocks are advancing broadly over the short term, but the available news supports only a cautious extension of the existing medtech recovery theme. Learn more: https://axlfi.com/themes/momentum/676
0 replies
Following_the_trend Oct 22, 2:57 PM
$ALC VERY nice. Dilution possible in 2027 though.
0 replies
filecrux Oct 20, 8:58 PM
$ALC (Alcon, the Swiss eye-care company) paid $550M upfront for private Neurotech, maker of ENCELTO, the only FDA-approved MacTel Type 2 treatment, and expects the deal slightly dilutive to core EPS in 2027, accretive after. That's ~1.7% of its ~$33.06B market value at $67.82 (16:00 ET Oct 20, 2026) and ~41% of its $1.355B cash at June 30, 2026. In return it gets a US-only approved therapy for ~25,000 diagnosed US patients, seen modestly lifting sales growth. More payments may come on commercial milestones; no dates given.
0 replies
ReversalRuler Oct 20, 3:53 AM
$ALC I’d be glad to see even a small sign of progress.
0 replies
KryptonResearch14 Oct 17, 7:01 AM
$ALC FDA cleared Brytly on Friday, Alcon's apraclonidine 0.125% drops for eye redness, the first OTC product with that ingredient, cleared for ages 12 and up. Alcon says one drop works in a minute and lasts up to 12 hours. That's a label comparison, not a head-to-head trial, Lumify's label tops out at 8 hours, and Brytly is not in stores for a few months yet.
0 replies
flychicken1991 Oct 16, 12:57 PM
$ALC FDA Approves New Nonprescription Eye Drop for Relief of Eye Redness. Impact: Positive (87%). The approval modestly supports ALC's stock valuation by enabling an additional nonprescription product revenue opportunity; the supplied evidence does not establish a meaningful earnings uplift. Source and what to watch next: https://nimpact.tech/newsimpact/news/90e1343173fd6c45/alc-fda-approves-new-nonprescription-eye-drop-for-relief-of-eye-redness?utm_source=stocktwits&utm_medium=story_url
0 replies
dustlesspuma Oct 14, 2:25 AM
🔴 $ALC 62.5P Nov 20 💰 $275,000 premium 💵 $2.75/contract 📊 9.8x Vol/OI 📍 Spot $63.05 💰 Large premium | 🚨 Repeat sweep 🌊 Dark Flow | Options Flow
0 replies